Találati lista | Tudóstér

001-es BibID:	BIBFORM083270
035-os BibID:	(cikkazonosító)101868 (PMID)31877445
Első szerző:	Kunchok, Amy
Cím:	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder / Amy Kunchok, Charles Malpas, Petra Nytrova, Eva Kubala Havrdova, Raed Alroughani, Murat Terzi, Bassem Yamout, Jyh Yung Hor, Rana Karabudak, Cavit Boz, Serkan Ozakbas, Javier Olascoaga, Magdolna Simo, Franco Granella, Francesco Patti, Pamela McCombe, Tunde Csepany, Bhim Singhal, Roberto Bergamaschi, Yara Fragoso, Talal Al-Harbi, Recai Turkoglu, Jeannette Lechner-Scott, Guy Laureys, Celia Oreja-Guevara, Eugenio Pucci, Patrizia Sola, Diana Ferraro, Ayse Altintas, Aysun Soysal, Steve Vucic, Francois Grand'Maison, Guillermo Izquierdo, Sara Eichau, Alessandra Lugaresi, Marco Onofrj, Maria Trojano, Mark Marriott, Helmut Butzkueven, Ilya Kister, Tomas Kalincik
Dátum:	2020
ISSN:	2211-0348
Megjegyzések:	Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG+NMOSD are typically measured by relapse rate and disability. Using the MSBase, a multi-centre international registry, we aimed to examine the impact immunosuppressive therapies and patient characteristics as predictors of disease outcome measures in AQP4-IgG+NMOSD. METHOD: This MSBase cohort study of AQP4-IgG+NMOSD patients examined modifiers of relapse in a multivariable proportional hazards model and expanded disability status score (EDSS) using a mixed effects model. RESULTS: 206 AQP4-IgG+ patients were included (median follow-up 3.7 years). Age (hazard ratio [HR] = 0.82 per decade, p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p<0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p<0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p<0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). INTERPRETATION: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Disability Immunosuppression Neuromyelitis optica spectrum disorder Predictors Relapses Therapy
Megjelenés:	Multiple Sclerosis and Related Disorders. - 38 (2020), p. 1-8. -
További szerzők:	Malpas, Charles Nytrova, Petra Havrdova, Eva Alroughani, Raed Terzi, Murat Yamout, Bassem Hor, Jyh Yung Karabudak, Rana Boz, Cavit Ozakbas, Serkan Olascoaga, Javier Simó Magdolna Granella, Franco Patti, Francesco McCombe, Pamela Csépány Tünde (1956-) (neurológus, pszichiáter) Singhal, Bhim Bergamaschi, Roberto Fragoso, Yara Al-Harbi, Talal Turkoglu, Recai Lechner-Scott, Jeannette Laureys, Guy Oreja-Guevara, Celia Pucci, Eugenio Sola, Patrizia Ferraro, Diana Altintas, Ayse Soysal, Aysun Vucic, Steve Grand'Maison, Francois Izquierdo, Guillermo Eichau, Sara Lugaresi, Alessandra Onofrj, Marco Trojano, Maria Marriott, Mark Butzkueven, Helmut Kister, Ilya Kalincik, Tomas
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: